Source comparison
Best SS-31 Dosage for Heart Failure: Dosing and Outcome Comparison
0.25mg/kg/hour × 4 hours (single infusion) Intravenous, one-time +3.1% LVEF, −5.2mL LVESV 8% (mostly infusion site reactions) Acute decompensated HF stabilisation Best for short-term functional improvement without sustained dosing commitment 1mg/kg daily × 28
This comparison does not assign a generated winner or score.
- 0.25mg/kg/hour × 4 hours (single infusion)
- Intravenous, one-time
- +3.1% LVEF, −5.2mL LVESV
- 8% (mostly infusion site reactions)
- Acute decompensated HF stabilisation
- Best for short-term functional improvement without sustained dosing commitment
- 1mg/kg daily × 28 days
- Subcutaneous, daily
- +42m 6MWT, −18% NT-proBNP
- 12% (injection site, mild hypotension)
- Chronic HFrEF with reduced exercise capacity
- Optimal balance of efficacy and tolerability for sustained mitochondrial protection
- 4mg/kg daily × 28 days
- +58m 6MWT, −22% NT-proBNP
- 26% (injection site, hypotension, nausea)
- Severe HFrEF (EF <25%) with high symptom burden
- Maximum benefit but dropout risk. Reserve for patients failing standard therapy
- 0.5mg/kg every 3 days × 28 days
- Subcutaneous, intermittent
- +1.8% LVEF, −12% NT-proBNP
- 6% (minimal)
- Mild-moderate HFrEF (EF 30–40%)
- Minimal intervention for patients intolerant of daily injections or with preserved QOL